Home > Publications database > The Role of Tau Imaging in Parkinsonian Disorders > print

001     856060
005     20210129235230.0
024 7 _ |a 10.1007/s11910-018-0898-3
|2 doi
024 7 _ |a 1528-4042
|2 ISSN
024 7 _ |a 1534-6293
|2 ISSN
024 7 _ |a pmid:30293094
|2 pmid
024 7 _ |a WOS:000446537500003
|2 WOS
024 7 _ |a altmetric:49470336
|2 altmetric
037 _ _ |a FZJ-2018-05725
082 _ _ |a 610
100 1 _ |a Hammes, Jochen
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a The Role of Tau Imaging in Parkinsonian Disorders
260 _ _ |a Philadelphia, Pa.
|c 2018
|b Current Science Inc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1539094296_10156
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Purpose of ReviewDifferential diagnosis of atypical Parkinson syndromes (APS) is difficult as clinical presentations may vary and as there is a strong overlap between disease entities. Aggregations of misfolded and hyperphosphorylated tau proteins are the common denominator of many of these diseases.Recent FindingsSeveral tau targeting positron emission tomography (PET) tracers have been evaluated as possible biomarkers in APS in the recent years. For Parkinson’s disease, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration, promising results have been reported with regard to the ability to detect the presence of disease and to discriminate patients from controls. However, the discussion about the specificity of the first-generation radiotracers and their value in the clinical context is ongoing.SummaryA combined interpretation of signal strength and distribution pattern in PET scans with first- and second-generation tracers may be helpful in clinical diagnosis and follow-up of patients with APS
536 _ _ |a 572 - (Dys-)function and Plasticity (POF3-572)
|0 G:(DE-HGF)POF3-572
|c POF3-572
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Drzezga, Alexander
|0 P:(DE-HGF)0
|b 1
700 1 _ |a van Eimeren, Thilo
|0 P:(DE-Juel1)169110
|b 2
773 _ _ |a 10.1007/s11910-018-0898-3
|g Vol. 18, no. 12, p. 86
|0 PERI:(DE-600)2094171-7
|n 12
|p 86
|t Current neurology and neuroscience reports
|v 18
|y 2018
|x 1534-6293
856 4 _ |u https://juser.fz-juelich.de/record/856060/files/Hammes2018_Article_TheRoleOfTauImagingInParkinson.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/856060/files/Hammes2018_Article_TheRoleOfTauImagingInParkinson.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:856060
|p VDB
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)169110
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-572
|2 G:(DE-HGF)POF3-500
|v (Dys-)function and Plasticity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2018
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CURR NEUROL NEUROSCI : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21